Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

98Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA1c, low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. © 2008 Elsevier Ireland Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Russell-Jones, D. (2009). Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Molecular and Cellular Endocrinology, 297(1–2), 137–140. https://doi.org/10.1016/j.mce.2008.11.018

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free